• Gilad Yahalom, Yael Orlev, Oren S Cohen, Evgenia Kozlova, Eitan Friedman, Rivka Inzelberg, and Sharon Hassin-Baer.
• The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
• Mov. Disord. 2014 Jul 1; 29 (8): 1057-60.

IntroductionIn this retrospective study, we compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers.MethodsConsecutive PD patients were recruited between 2004 and 2011. Disease progression of carriers versus noncarriers was compared using survival analysis, where the end-point was the time from PD onset to reaching Hoehn and Yahr stage 3 (HY3).ResultsOverall, 405 AJ PD patients (males = 241[60%]) were genotyped, of whom 60 (males = 30) were LRRK2*G2019S mutation carriers. Time to HY3 did not differ significantly between mutation carriers and noncarriers (hazard ratio = 1.21, 95%CI = 0.83-1.77, P = 0.33). Age at PD onset was younger for carriers than for noncarriers (59.1 ± 9.8 vs. 63.2 ± 12.0 years, respectively; P = 0.005). In both groups, young age at onset was strongly associated with longer time to HY3, (P < 0.001).ConclusionThe LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in AJ PD patients.© 2014 International Parkinson and Movement Disorder Society.

27 keywords...

hide…